Business Description
BerGenBio ASA
ISIN : NO0013251173
Description
BerGenBio ASA is a clinical-stage biopharmaceutical Company focused on developing novel medicines for aggressive diseases. The company's clinical asset, bemcentinib, targeting the receptor tyrosine kinase AXL, is currently in development in a Ph1b/2a study in 1L STK 11 mutated NSCLC and preclinical development for severe respiratory infections.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 418.29 | |||||
| Equity-to-Asset | 0.79 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 3.43 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -66.9 | |||||
| 3-Year EBITDA Growth Rate | 64.5 | |||||
| 3-Year EPS without NRI Growth Rate | 64.7 | |||||
| 3-Year FCF Growth Rate | 61.2 | |||||
| 3-Year Book Growth Rate | -80.7 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 25.38 |
Momentum Rank
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.71 | |||||
| Quick Ratio | 4.71 | |||||
| Cash Ratio | 4.23 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -198.5 | |||||
| Shareholder Yield % | -42.24 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -30950.67 | |||||
| Net Margin % | -29229.94 | |||||
| FCF Margin % | -26677.35 | |||||
| ROE % | -107.15 | |||||
| ROA % | -83.59 | |||||
| ROIC % | -608.69 | |||||
| ROC (Joel Greenblatt) % | -48476.92 | |||||
| ROCE % | -110.84 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 442.95 | |||||
| PB Ratio | 2.14 | |||||
| Price-to-Tangible-Book | 2.15 | |||||
| EV-to-EBIT | -0.98 | |||||
| EV-to-Forward-EBIT | -0.82 | |||||
| EV-to-EBITDA | -0.98 | |||||
| EV-to-Forward-EBITDA | -0.82 | |||||
| EV-to-Revenue | 295.8 | |||||
| EV-to-FCF | -1.11 | |||||
| Price-to-Net-Current-Asset-Value | 2.15 | |||||
| Price-to-Net-Cash | 2.46 | |||||
| Earnings Yield (Greenblatt) % | -102.04 | |||||
| FCF Yield % | -42.25 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
BerGenBio ASA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 0.521 | ||
| EPS (TTM) (kr) | -4.569 | ||
| Beta | 0 | ||
| Volatility % | 55.66 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (kr) | 5.465617 | ||
| 20-Day SMA (kr) | 10.9844 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (kr) | 9.999 - 344.5 | ||
| Shares Outstanding (Mil) | 39.09 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
BerGenBio ASA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
BerGenBio ASA Stock Events
| Event | Date | Price(kr) | ||
|---|---|---|---|---|
| No Event Data | ||||
BerGenBio ASA Frequently Asked Questions
What is BerGenBio ASA(OSTO:BGBIOO)'s stock price today?
The current price of OSTO:BGBIOO is kr10.00. The 52 week high of OSTO:BGBIOO is kr344.50 and 52 week low is kr10.00.
When is next earnings date of BerGenBio ASA(OSTO:BGBIOO)?
The next earnings date of BerGenBio ASA(OSTO:BGBIOO) is 2025-02-19.
Does BerGenBio ASA(OSTO:BGBIOO) pay dividends? If so, how much?
BerGenBio ASA(OSTO:BGBIOO) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers